Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Beyne-Rauzy

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Thrombosis and Haemostasis : JTH|July 7, 2018
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adultsM-L Piel-Julian, M Mahévas, J Germain, et al.
Leukemia|August 24, 2007
Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cellsN Prade-Houdellier, E Frébet, C Demur, et al.
Leukemia|July 11, 2008
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulumE Gyan, E Frisan, O Beyne-Rauzy, et al.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia Research|August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDSS Park, R Sapena, C Kelaidi, et al.
British Journal of Haematology|May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyL Mannone, C Gardin, M C Quarre, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 casesR Itzykson, S Ayari, D Vassilief, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Thrombosis and Haemostasis : JTH|July 7, 2018
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adultsM-L Piel-Julian, M Mahévas, J Germain, et al.
Leukemia|August 24, 2007
Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cellsN Prade-Houdellier, E Frébet, C Demur, et al.
Leukemia|July 11, 2008
Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulumE Gyan, E Frisan, O Beyne-Rauzy, et al.
Leukemia|April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasR Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia Research|August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDSS Park, R Sapena, C Kelaidi, et al.
British Journal of Haematology|May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyL Mannone, C Gardin, M C Quarre, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Leukemia|January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 casesR Itzykson, S Ayari, D Vassilief, et al.
Leukemia Research|June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromesG Caocci, M T Voso, E Angelucci, et al.
Pageof 3